**Supplementary Table 9. Clinical baseline characteristics of survival group and death or LT group**

|  |  |  |  |
| --- | --- | --- | --- |
| 　 | Survival group | Death or LT group | *P* value |
| 　 | (n=5) | (n=5) | 　 |
| Age (y) | 48 ± 13 | 46 ± 7 | 0.776  |
| Sex, male | 3 (60) | 5 (100) | 0.114  |
| Liver cirrhosis | 4 (80) | 4 (80) | 1.000  |
| Infection | 2 (40) | 3 (60) | 0.527  |
| AST (U/L) | 642 (142,1131) | 409 (233,1091) | 0.754  |
| ALT (U/L) | 798 (185,1611) | 477 (248,1025) | 0.602  |
| ALB (g/L) | 35 ± 4 | 35 ± 5 | 0.943  |
| TBIL (umol/L) | 299 ± 34 | 391 ± 142 | 0.195  |
| TBA (umol/L) | 302 ± 56 | 276 ± 20 | 0.386  |
| BUN (mmol/L） | 3.5 ± 1.3 | 3.5 ± 0.8 | 0.982  |
| Cr (umol/L) | 62 ± 12 | 84 ± 26 | 0.121  |
| PT (sec) | 19.5 ± 1.2 | 21.9 ± 2.5 | 0.081  |
| PT-INR | 1.6 ± 0.1 | 1.9 ± 0.3 | 0.064  |
| K (mmol/L) | 3.7 ± 0.5 | 3.7 ± 0.4 | 0.846  |
| Na (mmol/L) | 140 ± 2 | 136 ± 5 | 0.145  |
| WBC (×109/L) | 5.5 ±1.6 | 7.2 ± 3.2 | 0.290  |
| NEU% |  0.68 ± 0.07 | 0.66 ± 0.05 | 0.715  |
| PCT (ng/l) | 0.62 ± 0.26 | 0.74 ± 0.28 | 0.507  |
| IL-6 (ng/l) | 14.6 ± 7.2 | 20.8 ± 8.7 | 0.282  |
| lgHBV-DNA | 5.3 ± 2.2 | 5.4 ± 2.0 | 0.915  |
| MELD score | 19.2 ± 1.9 | 24.4 ± 5.7 | 0.090  |
| COSSH-ACLF Ⅱ score | 6.3 ± 0.5 | 6.9 ± 1.0 | 0.261  |

Independent samples *t-*test and Mann-Whitney *U* test were used for the comparison of continuous variables between groups. Data are presented as mean ± standard deviation, median (interquartile range); categorical variables are presented as frequency (percentage) and were compared using the Chi-square test. TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; GGT, gamma-glutamyl endopeptidase; TBA, total bile acid; PT, prothrombin time; INR, international normalized ratio; BUN, blood urea nitrogen; Cr, creatinine; K, serum kalium; Na, serum sodium; WBC, white blood cell; NEU, neutrophil; HGB, hemoglobin; platelet, PLT; PCT, procalcitonin; IL, interleukin; MELD, model for end-stage liver disease; COSSH-ACLF, Chinese Group on the Study of Severe Hepatitis B-Acute-on-Chronic Liver Failure; LT, liver transplantation.